A phase Ib, multi-arm, open-label, study of HDM201 in combination with MBG453 or venetoclax in adult subjects with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Novartis Pharmaceuticals Corporation
Start Date
January 7, 2020
End Date
February 28, 2022
Administered By
Duke Cancer Institute
Awarded By
Novartis Pharmaceuticals Corporation
Start Date
January 7, 2020
End Date
February 28, 2022